<?xml version="1.0" encoding="UTF-8"?>
<p id="Par21">To estimate the DALYs averted by mass antiviral treatment, we again pair baseline and treatment simulations. To translate infections averted into healthy life years gained, we apply a published model
 <sup>
  <xref ref-type="bibr" rid="CR22">22</xref>
 </sup> that considers US age-specific risks, disability weights, and durations of clinical outcomes. To quantify the direct benefits for treated cases, we estimate the years averted owing to alleviation of influenza symptoms using baloxavir or oseltamivir
 <sup>
  <xref ref-type="bibr" rid="CR8">8</xref>
 </sup> (Supplementary SectionÂ 
 <xref rid="MOESM1" ref-type="media">5</xref>).
</p>
